Evofem Biosciences IncChange company Symbol lookupSelect an option...EVFM Evofem Biosciences IncFCO Aberdeen Global Income Fund Inc.DTEC ALPS Disruptive Technologies ETF$RUIRETAILT Russell 1000 RGS Retail Total ReturnBAC Bank of America CorpMA Mastercard IncAAPL Apple IncAA Alcoa CorpAMD Advanced Micro Devices IncPFE Pfizer IncGo
Change company Symbol lookup
Select an option...
EVFM Evofem Biosciences Inc
FCO Aberdeen Global Income Fund Inc.
DTEC ALPS Disruptive Technologies ETF
$RUIRETAILT Russell 1000 RGS Retail Total Return
BAC Bank of America Corp
MA Mastercard Inc
AAPL Apple Inc
AA Alcoa Corp
AMD Advanced Micro Devices Inc
PFE Pfizer Inc
Health Care : Pharmaceuticals | Small Cap Value
Company profileEvofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q3 ending 09/2020) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q3 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced November 9, 2020 | -$0.37 | Q3 Consensus of 4 analysts | -$0.44 | Difference from consensus | 18.92% | Q4 Earnings will announce | (Unconfirmed) March 10, 2021 |
Quarterly Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
EVFM's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.